Avastin Loses Its Breast Cancer Claim; FDA’s Hamburg Opts For Withdrawal Over Restrictions
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA Commissioner Margaret Hamburg says Genentech has failed to identify a subpopulation of patients in whom the clinical benefits outweigh the risks. The company says it will not appeal the indication’s withdrawal but will pursue a new study in breast cancer.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
